QLT PhotoTherapeutics Inc. is a world leader in the development and commercialization of proprietary pharmaceutical products for use in photodynamic therapy an emerging field of medicine utilizing light-activated drugs in the treatment of disease. QLT's innovative science has advanced photodynamic therapy beyond applications in cancer towards potential breakthrough treatments in ophthalmology and autoimmune disease. (PRESS RELEASE) Qlt Inc. has a market cap of $184 million; its shares were traded at around $3.37 with a P/E ratio of 16 and P/S ratio of 1.5.
QLTI is in the portfolios of Charles Brandes of Brandes Investment, Arnold Van Den Berg of Century Management.
Insiders' Positions with QLTI
- Buy:: Director Ian J Massey bought 14,490 shares of QLTI stock on 05/14/2009 at the average price of 2.08, the price of the stock has increased by 62.02% since
- Buy:: Director Bruce L A Carter bought 20,000 shares of QLTI stock on 05/14/2009 at the average price of 2.07, the price of the stock has increased by 62.8% since
- Buy:: Director Peter A Crossgrove bought 10,000 shares of QLTI stock on 05/13/2009 at the average price of 2.17, the price of the stock has increased by 55.3% since
- Buy:: Director C Boyd Clarke bought 10,000 shares of QLTI stock on 05/12/2009 at the average price of 2.21, the price of the stock has increased by 52.49% since
- Sell:: 10% Owner Public Equity K/s Nb sold 2,000,000 shares of QLTI stock on 10/21/2009 at the average price of 3.2, the price of the stock has increased by 5.31% since
Become a Premium Member to See This: (Free Trial):
- CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
- Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
- Double Buys:: Companies that both Gurus and Insiders are buying
- Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.
Rate This Article: |
  |